Selva Therapeutics Overview
- Year Founded
-
2017
- Status
-
Out of Business
- Employees
-
4
- Latest Deal Type
-
Out of Business
- Investors
-
1
Selva Therapeutics General Information
Description
Operator of a biotechnology company intended to develop therapeutics for treating certain viral and parasitic infectious diseases. The company offers a lead compound available as a small molecule novel antiviral therapy with activity against a broad range of viruses that threaten global health from binding to receptors needed for entry into human lung cells, enabling healthcare institutes to get a therapy against several viruses, either as a single oral agent or in combination with direct-acting antivirals.
Contact Information
Website
www.selvarx.comCorporate Office
- 2905 Hacienda Street
- San Mateo, CA 94403
- United States
Corporate Office
- 2905 Hacienda Street
- San Mateo, CA 94403
- United States
Selva Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Out of Business | 15-Jan-2026 | Completed | Out of Business | |||
| 3. Later Stage VC | 01-Sep-2023 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 27-Oct-2020 | $3M | $3M | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2017 | Completed | Startup |
Selva Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Selva Therapeutics Patents
Selva Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026030705-A1 | Combination therapeutics for antiviral treatment | Pending | 02-Aug-2024 | ||
| US-20250195506-A1 | Combination therapeutics for antiviral treatment | Pending | 14-Dec-2023 | ||
| CA-3173931-A1 | Viral entry inhibitors and rna polymerase inhibitors | Pending | 03-Apr-2020 | ||
| EP-4125989-A1 | Viral entry inhibitors and rna polymerase inhibitors | Pending | 03-Apr-2020 | ||
| EP-4125989-A4 | Viral entry inhibitors and rna polymerase inhibitors | Pending | 03-Apr-2020 | A61K31/445 |
Selva Therapeutics Signals
Selva Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| University of California, San Diego | University |
Selva Therapeutics FAQs
-
When was Selva Therapeutics founded?
Selva Therapeutics was founded in 2017.
-
Where is Selva Therapeutics headquartered?
Selva Therapeutics is headquartered in San Mateo, CA.
-
What is the size of Selva Therapeutics?
Selva Therapeutics has 4 total employees.
-
What industry is Selva Therapeutics in?
Selva Therapeutics’s primary industry is Drug Discovery.
-
Is Selva Therapeutics a private or public company?
Selva Therapeutics is a Private company.
-
What is Selva Therapeutics’s current revenue?
The current revenue for Selva Therapeutics is .
-
How much funding has Selva Therapeutics raised over time?
Selva Therapeutics has raised $3M.
-
Who are Selva Therapeutics’s investors?
University of California, San Diego has invested in Selva Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process